Insulet (NASDAQ: PODD) reported Q3 EPS of $0.45, $0.29 better than the analyst estimate of $0.16. Revenue for the quarter came in at $340.8 million versus the consensus estimate of $313.06 million.

GUIDANCE:

2022 Outlook

Revenue Guidance (in constant currency):

For the year ending December 31, 2022, the Company is raising its revenue growth guidance range to 18% to 19% (previously 14% to 17%). Revenue growth ranges by product line are:

Total Omnipod of 23% to 24% (previously 18% to 21%)

U.S. Omnipod of 30% to 31% (previously 23% to 26%)
International Omnipod of 11% to 12% (previously 9% to 12%)

Drug Delivery of (37)% to (35)% (previously (40)% to (35)%)

For the quarter ending December 31, 2022, the Company expects revenue growth of 11% to 14%. Revenue growth ranges by product line are:

Total Omnipod of 23% to 26%

U.S. Omnipod of 27% to 30%
International Omnipod of 15% to 18%

Drug Delivery of (100)% to (92)%

For earnings history and earnings-related data on Insulet (PODD) click here.